Angiogenesis as a strategic target for ovarian cancer therapy

Whitney A Spannuth1, Anil K Sood, Robert L Coleman

  • 1Departments of Gynecologic Oncology and Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, Texas 77230-1439, USA.

Insights

Tumor angiogenesis, vital for cancer spread, is targeted by new drugs. This review covers recent clinical trials of antivascular agents in ovarian cancer, noting promising results and future directions.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Angiogenesis is essential for tumor growth and metastasis.
  • Understanding tumor angiogenesis has identified new therapeutic targets.
  • Novel antivascular agents are being developed to inhibit tumor blood vessel formation.

Purpose of the Study:

  • To review the latest clinical studies of antivascular agents in ovarian cancer.
  • To discuss the efficacy and challenges of these agents.
  • To explore future opportunities for clinical trials in ovarian cancer.

Main Methods:

  • Literature review of recent clinical trials.
  • Analysis of antivascular agents' performance in ovarian cancer.
  • Discussion of challenges and future prospects.

Main Results:

  • Antivascular agents show promising antitumor activity in ovarian cancer.
  • Clinical trials are evaluating the efficacy of these novel agents.
  • Significant progress has been made in understanding their therapeutic potential.

Conclusions:

  • Antivascular agents represent a promising therapeutic strategy for ovarian cancer.
  • Further clinical trials are needed to optimize treatment and overcome challenges.
  • Continued research into molecular mechanisms will drive future drug development.

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Mechanism of Angiogenesis01:10

Mechanism of Angiogenesis

Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...